Skip to content
Open access

Early assessment of pre-radiation therapy financial toxicity in prostate cancer from the navigator-assisted hypofractionation (NAVAH) clinical trial.

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

335 Background: Prostate cancer (PC) is the most common malignancy among men, and one of the leading causes of cancer-related mortality in the United States. Financial toxicity (FT) is defined as the harmful economic burden and financial distress associated with medical care. Patients at high risk of PC-related mortality (those of African-American and Native American race) may be at higher risk of experiencing disproportionately high FT. This study evaluates FT among high-risk patients enrolled in the Navigator-Assisted Hypofractionation (NAVAH) Program Phase I clinical trial prior to receipt of prostate radiation therapy (RT). Methods: African-American and Native American patients with pathologically confirmed PC undergoing curative-intent RT were prospectively enrolled. As part of the NAVAH clinical trial, patients were paired with a certified patient navigator for support throughout and following RT. FT was assessed using the 12-item COmprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire. This questionnaire was administered following patient consent for RT and prior to RT initiation to assess baseline FT. Composite COST-FACIT scores were calculated and classified into Grade 0 (score of 26-44; none), Grade 1 (14-25; mild), Grade 2 (1-13; moderate), and Grade 3 (0; severe), with higher grade indicating worse FT. Personal FT was derived from COST-FACIT questions 1-11, while familial FT was derived from question number 12. The Pearson correlation coefficient was used to assess statistical significance, set at p<0.05. Results: The first ten patients enrolled provided pre-RT baseline FT data. Mean baseline COST-FACIT score was 20.5 +/- 12.2 (range, 4-41). Four patients met criteria for Grade 0, while two patients experienced Grade 1 FT, and four patients experienced Grade 2 FT. Financial distress was prevalent across individual questionnaire domains. Most participants reported feeling a lack of choice about healthcare expenses (90%), higher out of pocket costs than anticipated (80%), and frustration over inability to work or contribute financially (80%). 62.5% of patients with Grade 1+ FT reported familial impact of FT. The correlation between personal and familial FT was statistically significant (r=0.907, p=0.000). Conclusions: Our early Phase I trial findings suggest that baseline FT is common among patients with a historically high-risk of cancer-related mortality with PC undergoing definitive RT. Financial toxicity impacts patients at the individual and familial levels with individual financial toxicity significantly correlating with familial FT. These results underscore the importance of early identification of financial toxicity and the potential role of financial assistance in this patient population prior to receipt of curative therapy. Clinical trial information: NCT07014618 .

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.